1. Home
  2. CZNC vs CBIO Comparison

CZNC vs CBIO Comparison

Compare CZNC & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Citizens & Northern Corp

CZNC

Citizens & Northern Corp

HOLD

Current Price

$22.85

Market Cap

423.4M

Sector

Finance

ML Signal

HOLD

Logo Crescent Biopharma Inc.

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$17.34

Market Cap

471.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CZNC
CBIO
Founded
1864
2003
Country
United States
United States
Employees
N/A
44
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
423.4M
471.3M
IPO Year
2009
N/A

Fundamental Metrics

Financial Performance
Metric
CZNC
CBIO
Price
$22.85
$17.34
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$23.50
$26.67
AVG Volume (30 Days)
70.8K
326.5K
Earning Date
05-12-2026
04-29-2026
Dividend Yield
4.87%
N/A
EPS Growth
7.64
N/A
EPS
0.02
N/A
Revenue
N/A
N/A
Revenue This Year
$3.11
N/A
Revenue Next Year
N/A
$279.20
P/E Ratio
$1,139.50
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.16
$8.72
52 Week High
$24.25
$27.41

Technical Indicators

Market Signals
Indicator
CZNC
CBIO
Relative Strength Index (RSI) 55.18 46.33
Support Level $21.28 $17.02
Resistance Level $24.01 $19.13
Average True Range (ATR) 0.61 1.23
MACD -0.02 -0.00
Stochastic Oscillator 51.96 34.84

Price Performance

Historical Comparison
CZNC
CBIO

About CZNC Citizens & Northern Corp

Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: